Daiichi Sankyo Executive and Leadership Team

Joji Nakayama, the Representative Director, President and Chief Executive Officer at Daiichi Sankyo, directs the company's overarching strategy and global operations. Nakayama's leadership guides the development and provision of innovative medicines, ensuring Daiichi Sankyo serves patients in over 30 countries. This executive role involves setting the strategic vision for drug discovery and delivery methods, aligning all departments toward advancing patient care. The Chief Executive Officer's mandate includes fostering a culture of innovation and operational excellence across the global enterprise. Joji Nakayama's strategic direction is crucial for maintaining the company's market position and driving future growth in the pharmaceutical sector. This leadership ensures the company's mission of contributing to the enrichment of quality of life is consistently pursued.

Kazuki Mori, the Chief of Staff To Chief Executive Officer at Daiichi Sankyo, provides direct strategic and operational support to the CEO. Mori coordinates key initiatives, facilitates communication between the CEO and various departments, and manages critical projects aligned with the company's strategic vision. This role is essential for ensuring the efficient execution of the CEO's directives and advancing Daiichi Sankyo's mission of pharmaceutical innovation. The Chief of Staff To Chief Executive Officer's responsibilities include streamlining executive decision-making processes and enhancing organizational alignment. Kazuki Mori's support is crucial for driving forward the development and provision of new and generic medicines, serving patients in over 30 countries. This position ensures strategic priorities are effectively translated into action.

Hiroyuki Okuzawa, the Chief Financial Officer at Daiichi Sankyo, manages the company's financial health and strategic fiscal planning. Okuzawa oversees all financial operations, including budgeting, forecasting, and investment strategies, ensuring robust financial management across the global enterprise. This role is critical for supporting Daiichi Sankyo's mission of delivering innovative medicines and advanced drug discovery methods. The Chief Financial Officer's responsibilities extend to optimizing financial resources to facilitate patient access to treatments in over 30 countries. Hiroyuki Okuzawa's expertise guides financial decision-making, directly impacting the company's ability to fund research and development initiatives. This leadership ensures fiscal discipline and supports sustainable growth, reinforcing Daiichi Sankyo's commitment to improving global quality of life through pharmaceutical advancements.

Koji Ogawa, the Chief Financial Officer & Head, Global Corporate Planning & Management at Daiichi Sankyo, directs financial strategy and corporate planning initiatives. Ogawa's dual role encompasses managing the company's financial resources while also spearheading global corporate planning and management functions. This executive oversees the strategic alignment of business objectives with financial capabilities, ensuring efficient resource allocation for drug discovery and delivery. The Head, Global Corporate Planning & Management's focus is on long-term strategic development and operational efficiency across Daiichi Sankyo's international presence. Koji Ogawa's leadership ensures that financial prudence and strategic foresight are integrated, supporting the company's mission to provide innovative medicines to patients worldwide. This comprehensive oversight drives sustainable growth and enhances market competitiveness.

Chloe Stern, the Manager, Chief Financial Officer Planning Department at Daiichi Sankyo, executes critical financial planning functions. Stern manages departmental operations, contributing to the strategic financial oversight managed by the Chief Financial Officer. This role involves detailed analysis and support for budgeting, forecasting, and resource allocation across Daiichi Sankyo's global operations. The Manager, Chief Financial Officer Planning Department's focus is on ensuring the accuracy and efficiency of financial planning processes, which are vital for supporting the company's drug discovery and delivery initiatives. Chloe Stern's diligent work underpins the financial stability required to serve patients in over 30 countries. This position is key to maintaining fiscal discipline and supporting strategic investments.

Hiroshi Sugiyama, the President at Daiichi Sankyo, directs significant operational segments of the global pharmaceutical business. Sugiyama's leadership focuses on advancing the company's portfolio of innovative medicines and drug discovery methods. This executive role is critical for ensuring Daiichi Sankyo effectively serves patients in over 30 countries with essential treatments. The President's responsibilities include driving strategic initiatives that enhance market presence and patient access to advanced pharmaceutical solutions. Hiroshi Sugiyama's oversight contributes to the company's commitment to improving global quality of life through scientific advancement and operational excellence. This leadership ensures sustained progress in delivering vital healthcare solutions.

Suthas Thongprasert, the President at Daiichi Sankyo, leads key strategic initiatives and operational functions within the organization. Thongprasert's executive focus is on driving the development and delivery of innovative pharmaceutical products, aligning with Daiichi Sankyo's global mission. This leadership position is vital for expanding patient access to essential medicines and advanced drug discovery techniques across international markets. The President's responsibilities include fostering collaborations and optimizing operational frameworks to enhance the company's impact. Suthas Thongprasert's contributions are instrumental in advancing Daiichi Sankyo's commitment to improving patient outcomes and global health. This leadership ensures robust execution of strategic objectives.

Caitlin Barnabo, the Global Oncology Medical Affairs Chief of Staff at Daiichi Sankyo, supports the strategic execution of oncology medical affairs initiatives worldwide. Barnabo coordinates key activities and ensures seamless communication across global oncology teams, facilitating the advancement of innovative cancer treatments. This role is vital for translating scientific insights into actionable medical strategies, aligning with Daiichi Sankyo's commitment to patient care. The Global Oncology Medical Affairs Chief of Staff's responsibilities include optimizing operational workflows and supporting the development of advanced drug discovery and delivery methods in oncology. Caitlin Barnabo's contributions are essential for enhancing the impact of Daiichi Sankyo's oncology portfolio, ensuring patients benefit from cutting-edge pharmaceutical solutions. This leadership drives progress in a critical therapeutic area.

Kosuke Itagaki, the Chief of Staff & Global System Owner at Daiichi Sankyo, oversees critical operational systems and provides strategic support. Itagaki manages the implementation and maintenance of global systems, ensuring operational efficiency and data integrity across the enterprise. This role is integral to supporting Daiichi Sankyo's mission of delivering innovative medicines and advanced drug discovery methods. The Chief of Staff & Global System Owner's responsibilities include streamlining processes and enhancing system capabilities to facilitate patient access to treatments worldwide. Kosuke Itagaki's leadership ensures that technological infrastructure effectively supports the company's strategic objectives and operational demands. This focus on system optimization drives efficiency and supports global business continuity.